Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and oncology company Checkpoint Therapeutics for $355 million to bolster the Mumbai-based company’s drug portfolio.
On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M
Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer.
Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for ...
Sun Pharmaceutical Industries Ltd. closed 14.48% below its 52-week high of 1,960.20 rupees, which the company reached on ...
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...
The New Jersey Economic Development Authority board March 12 approved $5.24 million in tax credits under the Emerge Program ...
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...
Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...
The NJEDA Board approved tax credits under the Emerge Program to support Sun Pharmaceutical Industries Inc.’s plan to open a new ...
The country's top specialty generics company recently acquired US-based Checkpoint that will further its oncology portfolio ...
Sun Pharmaceutical Industries Ltd. closed 14.10% below its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.
Stay up-to-date with the Sun Pharma Stock Liveblog, your trusted source for real-time updates and thorough analysis of a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback